914 related articles for article (PubMed ID: 19538001)
21. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
22. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A
Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017
[TBL] [Abstract][Full Text] [Related]
23. [Hypertension 2007-2008].
Chatzikyrkou C; Menne J; Haller H
Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
[TBL] [Abstract][Full Text] [Related]
24. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
Weir MR
J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
[TBL] [Abstract][Full Text] [Related]
25. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
Dahlöf B
J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
[TBL] [Abstract][Full Text] [Related]
26. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
27. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
Gojanovic B; Feihl F; Liaudet L; Waeber B
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):1-9. PubMed ID: 18404602
[TBL] [Abstract][Full Text] [Related]
28. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
[TBL] [Abstract][Full Text] [Related]
29. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
30. Current status of antihypertensive prescription and associated blood pressure control in Japan.
Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
[TBL] [Abstract][Full Text] [Related]
31. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
Tocci G; Palano F; Pagannone E; Chin D; Ferrucci A; Volpe M
Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):115-23. PubMed ID: 19210207
[TBL] [Abstract][Full Text] [Related]
32. [The ACCOMPLISH trial: are results really unexpected?].
Waeber B; Feihl F
Rev Med Suisse; 2009 Jan; 5(185):25-8. PubMed ID: 19216321
[TBL] [Abstract][Full Text] [Related]
33. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
White WB
Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
[TBL] [Abstract][Full Text] [Related]
34. Exforge HCT.
Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888
[No Abstract] [Full Text] [Related]
35. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus.
Reboldi G; Gentile G; Angeli F; Verdecchia P
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1349-61. PubMed ID: 19900018
[TBL] [Abstract][Full Text] [Related]
36. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Volpe M; Tocci G
Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
[TBL] [Abstract][Full Text] [Related]
37. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
Riva N; Lip GY
Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
[TBL] [Abstract][Full Text] [Related]
39. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
40. Optimization of hypertension management: the role of angiotensin receptor blocker-calcium channel blocker combinations.
Parati G
J Cardiovasc Pharmacol; 2009 May; 53(5):352-8. PubMed ID: 19365281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
